Vaxcyte, Inc. (PCVX)
PCVX price $63.23 -3.00 -4.53%
- Ticker
- PCVX
- Price
- $63.23
- Change
- -3.00 -4.53%
- Market cap
- $9.95B
- P/E
- -8.28
- Forward P/E
- 85.06
- Sector
- Healthcare
- Industry
- Biotechnology
- Stocklytics score
- 67
Vaxcyte, Inc. is a biotechnology firm in the clinical development stage, dedicated to creating innovative protein-based vaccines. Its primary objective is to either prevent or manage bacterial infectious diseases. The company's leading vaccine candidate is VAX-24, an experimental 24-valent pneumococcal conjugate vaccine currently undergoing Phase 1/2 clinical trials, intended to address invasive pneumococcal disease…